Can Kailera become the next major GLP-1 challenger after pricing one of biotech’s biggest IPOs in years?
UCB SA (EBR: UCB) bets $1.15 bn on Neurona Therapeutics to push epilepsy treatment beyond symptom control
Read More Energy Industry News RWE’s Byers Gill solar and battery project wins approval as analysts weigh grid and pricing risks RWE AG wins approval for its 180 MW Byers Gill hybrid project, but grid delays and CfD pricing will determine investor confidence—read more. byPallavi MadhirajuJuly 24, 2025